CA2620915C - Methodes d'utilisation de l'acide (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylique pour le traitement du cancer - Google Patents

Methodes d'utilisation de l'acide (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylique pour le traitement du cancer Download PDF

Info

Publication number
CA2620915C
CA2620915C CA2620915A CA2620915A CA2620915C CA 2620915 C CA2620915 C CA 2620915C CA 2620915 A CA2620915 A CA 2620915A CA 2620915 A CA2620915 A CA 2620915A CA 2620915 C CA2620915 C CA 2620915C
Authority
CA
Canada
Prior art keywords
sns
dose
another embodiment
cancer
days
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
CA2620915A
Other languages
English (en)
Other versions
CA2620915A1 (fr
Inventor
Daniel C. Adelman
Jeffrey A. Silverman
Michelle Arkin
Jennifer Hyde
Duncan Walker
Jasmine Wright
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Viracta Therapeutics Inc
Original Assignee
Sunesis Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sunesis Pharmaceuticals Inc filed Critical Sunesis Pharmaceuticals Inc
Priority to CA2845095A priority Critical patent/CA2845095A1/fr
Priority claimed from PCT/US2006/034699 external-priority patent/WO2007028171A1/fr
Publication of CA2620915A1 publication Critical patent/CA2620915A1/fr
Application granted granted Critical
Publication of CA2620915C publication Critical patent/CA2620915C/fr
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

L'invention porte sur des méthodes de traitement, prévention et gestion des cancers dont certaines leucémies consistant à administrer de l'acide (+)-1,4-dihydro-7-[(3s,4s)-3-méthoxy-4-(méthylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylique énantiomèrement pur et sur des méthodes de traitement utilisant ce composé en association avec la chimiothérapie, la radiothérapie, l'hormonothérapie, des thérapies biologiques ou l'immunothérapie. L'invention porte également sur des préparations pharmaceutiques et des formes posologiques unitaires utilisables dans lesdites méthodes.
CA2620915A 2005-09-02 2006-09-05 Methodes d'utilisation de l'acide (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylique pour le traitement du cancer Expired - Fee Related CA2620915C (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CA2845095A CA2845095A1 (fr) 2005-09-02 2006-09-05 Methodes d'utilisation de l'acide (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylique pour le traitement du cancer

Applications Claiming Priority (11)

Application Number Priority Date Filing Date Title
US92150005P 2005-09-02 2005-09-02
US92150105P 2005-09-02 2005-09-02
US60/921,501 2005-09-02
US60/921,500 2005-09-02
US78892706P 2006-04-03 2006-04-03
US78909306P 2006-04-03 2006-04-03
US60/789,093 2006-04-03
US60/788,927 2006-04-03
US81028506P 2006-06-01 2006-06-01
US60/810,285 2006-06-01
PCT/US2006/034699 WO2007028171A1 (fr) 2005-09-02 2006-09-05 Methodes d'utilisation de l'acide (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylique pour le traitement du cancer

Related Child Applications (1)

Application Number Title Priority Date Filing Date
CA2845095A Division CA2845095A1 (fr) 2005-09-02 2006-09-05 Methodes d'utilisation de l'acide (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylique pour le traitement du cancer

Publications (2)

Publication Number Publication Date
CA2620915A1 CA2620915A1 (fr) 2007-03-08
CA2620915C true CA2620915C (fr) 2014-03-25

Family

ID=39687911

Family Applications (2)

Application Number Title Priority Date Filing Date
CA2620915A Expired - Fee Related CA2620915C (fr) 2005-09-02 2006-09-05 Methodes d'utilisation de l'acide (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylique pour le traitement du cancer
CA2845095A Abandoned CA2845095A1 (fr) 2005-09-02 2006-09-05 Methodes d'utilisation de l'acide (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylique pour le traitement du cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
CA2845095A Abandoned CA2845095A1 (fr) 2005-09-02 2006-09-05 Methodes d'utilisation de l'acide (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylique pour le traitement du cancer

Country Status (4)

Country Link
JP (1) JP5374153B2 (fr)
KR (2) KR20170118936A (fr)
CA (2) CA2620915C (fr)
RU (2) RU2592231C2 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2877848C (fr) * 2012-07-06 2021-11-02 St. Marianna University School Of Medicine Procede therapeutique et remede destine a des patients souffrant de myelopathie associee a htlv-1

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX9606331A (es) * 1994-06-14 1997-03-29 Dainippon Pharmaceutical Co Nuevos compuestos, procesos para la preparacion de los mismos y agentes antitumor.
JP4323574B2 (ja) * 1995-12-13 2009-09-02 大日本住友製薬株式会社 抗腫瘍剤
HUP0101110A3 (en) * 1997-10-27 2002-06-28 Reddys Lab Ltd Dr Bicyclic compounds, process for their preparation and pharmaceutical compositions containing them
FR2784678B1 (fr) * 1998-09-23 2002-11-29 Sod Conseils Rech Applic Nouveaux derives de n-(iminomethyl)amines, leur preparation, leur application a titre de medicaments et les compositions pharmaceutiques les contenant
US6458810B1 (en) * 2000-11-14 2002-10-01 George Muller Pharmaceutically active isoindoline derivatives
US6740757B2 (en) * 2001-08-29 2004-05-25 Pfizer Inc Enantiomers of 6-[(4-chloro-phenyl)-hydroxy-(3-methyl-3h-imidazol-4-yl)-methyl]-4-[3-(3-hydroxy-3-methyl-but-1-ynyl)-phenyl]-1-methyl-1h-quinolin-2-one and salts thereof, useful in the treatment of cancer
JP5317472B2 (ja) * 2004-03-15 2013-10-16 サネシス ファーマシューティカルズ， インコーポレイテッド Ｓｎｓ−５９５、及びその使用方法

Also Published As

Publication number Publication date
JP2009507042A (ja) 2009-02-19
RU2016124135A (ru) 2017-12-21
CA2845095A1 (fr) 2007-03-08
RU2592231C2 (ru) 2016-07-20
KR20140057409A (ko) 2014-05-12
KR20170118936A (ko) 2017-10-25
RU2011119345A (ru) 2012-11-20
JP5374153B2 (ja) 2013-12-25
CA2620915A1 (fr) 2007-03-08

Similar Documents

Publication Publication Date Title
US20180098975A1 (en) Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
DK2049109T3 (en) Combined use of (+) - 1,4-dihydro-7 - [(3S, 4S) -3-methoxy-4- (methylamino) -1-pyrrolidinyl] -4-oxo-1- (2-thiazolyl) -1,8-naphthyridine-3-carboxylic acid and cytarabine (Ara-C) for the treatment of leukemia
AU2006287149B2 (en) Methods of using (+)-1,4-dihydro-7-[(3S,4S)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
AU2015200944B2 (en) Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of antecedent hematologic disorders
CN101505753B (zh) 治疗癌症的化合物和组合物
US7893045B2 (en) Methods for treating lymphomas in certain patient populations and screening patients for said therapy
CA2620915C (fr) Methodes d'utilisation de l'acide (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylique pour le traitement du cancer
CA2766322A1 (fr) Methodes de traitement du cancer utilisant la corticoliberine (crf)
AU2013219242B2 (en) Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
AU2016210657A1 (en) Methods of using (+)-1,4-dihydro-7-[(3s,4s)-3-methoxy-4-(methylamino)-1-pyrrolidinyl]-4-oxo-1-(2-thiazolyl)-1,8-naphthyridine-3-carboxylic acid for treatment of cancer
CN104873502A (zh) 使用(+)-1,4-二氢-7-[(3s,4s)-3-甲氧基-4-(甲氨基)-1-吡咯烷基]-4-氧代-1-(2-噻唑基)-1,8-萘啶-3-羧酸治疗癌症的方法
RU2428983C2 (ru) Способы применения (+)-1,4-дигидро-7-[(3s,4s)-3-метокси-4-(метиламино)-1-пирролидинил]-4-оксо-1-(2-тиазолил)-1,8-нафтиридин-3-карбоновой кислоты для лечения рака
WO2008036954A1 (fr) Procédés et compositions pour le traitement du cancer
MX2008002843A (es) Metodos para usar acido (+)-1,4-dihidro-7-[(3s,4s)-3-metoxi-4-(met ilamino)-1-pirrolidinil]-4-oxo-1-(2-tiazolil)-1,8-naftitridin-3-c arboxilico para tratamiento de cancer.
CN101296697A (zh) 使用(+)-1,4-二氢-7-[(3s,4s)-3-甲氧基-4-(甲氨基)-1-吡咯烷基]-4-氧代-1-(2-噻唑基)-1,8-萘啶-3-羧酸治疗癌症的方法

Legal Events

Date Code Title Description
EEER Examination request
MKLA Lapsed

Effective date: 20200908

MKLA Lapsed

Effective date: 20200908